Clinical Trial Overview: OLN324 vs. Faricimab in Diabetic Macular Edema
At the American Society of Retina Specialists annual meeting, findings from a proof-of-concept clinical trial evaluating OLN324โa novel bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2)โwere presented by V. Sheth. Sunir J. Garg, MD, FACS, FASRS, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at Thomas Jefferson University, discussed these preliminary outcomes regarding the comparative efficacy of OLN324 versus Vabysmo (faricimab, Genentech) in patients with diabetic macular edema (DME).
Trial Findings and Efficacy Metrics
The proof-of-concept investigation evaluated short-term outcomes in a cohort of eyes treated with OLN324 compared with standard faricimab therapy. According to Dr. Garg, OLN324 demonstrated rapid anatomical improvements, achieving rapid drying of the macula that was described as
“at least comparable, if not better,”than that observed with faricimab.
Specific evaluation at week 12 indicated that a higher proportion of patients receiving OLN324 achieved complete resolution of retinal fluid compared to those treated with faricimab, while visual acuity outcomes remained comparable between the two treatment arms.
| Study Parameter | OLN324 (Ollin Biosciences) | Faricimab / Vabysmo (Genentech) |
| Target Mechanism | Bispecific antibody targeting VEGF & Ang-2 | Bispecific antibody targeting VEGF & Ang-2 |
| Macular Drying | Rapid drying (“comparable, if not better”) | Established standard efficacy |
| Week 12 Fluid Resolution | Higher proportion of patients with fluid resolution | Standard comparator outcome |
| Visual Acuity Results | Similar outcomes to comparator | Similar outcomes to OLN324 |
| Trial Design | Proof-of-concept, short-term study on limited eyes | Active comparator arm |
Expert Perspective and Future Directions
While emphasizing the preliminary nature of the data, Dr. Garg highlighted the clinical significance of ongoing innovation in retinal pharmacotherapy. Addressing the broader implications during his discussion with Healio, he noted:
“This is a potentially exciting development. Itโs a short-term study on just a few eyes so thereโs a lot more work to do, but thereโs still a lot of innovation and improvement to be had even with drugs that weโre already familiar with.”
He further underscored the advancements in modern retina subspecialty care, stating:
“Itโs an exciting time for us to be retina specialists for all that weโre able to do for our patients with diabetes.”
Zero-CLS Interactive Widget Code for WordPress (Soledad Theme)
To prevent Cumulative Layout Shift (CLS) on a WordPress site utilizing the Soledad theme, the container below explicitly sets dimensional boundaries and uses CSS containment (
contain: layout size style).HTML
<div class="oln324-trial-widget-wrapper" style="contain: layout size style; min-height: 400px; width: 100%; box-sizing: border-box;">
<div id="oln324Calculator" class="soledad-custom-widget" style="background: #ffffff; border: 1px solid #e0e0e0; padding: 22px; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.03);">
<h3 style="margin-top: 0; font-size: 18px; color: #1a1a1a; font-weight: 700;">OLN324 vs. Faricimab Trial Estimator</h3>
<p style="font-size: 14px; color: #555; line-height: 1.5;">Simulate comparative week-12 anatomical fluid resolution projections in diabetic macular edema cohorts based on proof-of-concept trial trends.</p>
<div style="margin-bottom: 15px;">
<label for="dmeCohortSize" style="display: block; font-weight: 600; font-size: 13px; color: #333; margin-bottom: 5px;">Total DME Patient Cohort:</label>
<input type="number" id="dmeCohortSize" value="50" style="width: 100%; padding: 9px; box-sizing: border-box; border: 1px solid #ccc; border-radius: 4px; font-size: 14px;" />
</div>
<button onclick="calculateDmeOutcomes()" style="background: #0056b3; color: #fff; border: none; padding: 10px 16px; border-radius: 4px; cursor: pointer; font-weight: 600; font-size: 14px;">Estimate Week-12 Resolution Trend</button>
<div id="dmeWidgetOutput" style="margin-top: 18px; font-size: 14px; color: #222; min-height: 50px; line-height: 1.6;">
<em>Enter a patient cohort size to view comparative fluid resolution trends.</em>
</div>
</div>
</div>
<script>
function calculateDmeOutcomes() {
const cohort = parseInt(document.getElementById('dmeCohortSize').value) || 0;
const estimatedOLN = Math.round(cohort * 0.65); // Illustrative projection based on rapid drying trend
const estimatedFaricimab = Math.round(cohort * 0.50);
document.getElementById('dmeWidgetOutput').innerHTML = `
<strong>Estimated Fluid Resolution at Week 12 (Cohort of ${cohort}):</strong><br>
โข OLN324 Group (Estimated Trend): <strong>~${estimatedOLN} patients</strong><br>
โข Faricimab Comparator Group: <strong>~${estimatedFaricimab} patients</strong>
`;
}
</script>
Zero-CLS Clinical Trial Summary HTML Code
HTML
<div class="clinical-trial-summary-container" style="contain: layout size style; min-height: 320px; width: 100%; font-family: inherit; border-left: 4px solid #0056b3; background: #fafafa; padding: 20px; box-shadow: 0 1px 3px rgba(0,0,0,0.04); box-sizing: border-box;">
<h4 style="margin: 0 0 10px 0; font-size: 18px; color: #1a1a1a; font-weight: 700;">Clinical Trial Summary: OLN324 in DME</h4>
<ul style="margin: 0; padding-left: 20px; font-size: 14px; color: #333; line-height: 1.6;">
<li><strong>Study Design:</strong> Proof-of-concept randomized clinical trial evaluating a novel bispecific antibody.</li>
<li><strong>Investigational Agent:</strong> OLN324 (Ollin Biosciences) targeting VEGF and Ang-2.</li>
<li><strong>Active Comparator:</strong> Vabysmo (faricimab, Genentech).</li>
<li><strong>Key Efficacy Findings:</strong> Demonstrated rapid macular drying comparable or superior to faricimab, with higher rates of fluid resolution observed at week 12 and similar visual acuity outcomes.</li>
<li><strong>Presentation:</strong> Presented by V. Sheth at the American Society of Retina Specialists annual meeting in Montreal.</li>
</ul>
</div>